Description
13,14-dihydro Prostaglandin E1-d4 (13,14-dh PGE1-d4) contains four deuterium atoms at the 3, 3', 4, and 4' positions. It is intended for use as an internal standard for the quantification of 13,14-dh PGE1 by GC- or LC-mass spectrometry. 13,14-dh PGE1 is an inhibitor of ADP-induced platelet aggregation in human platelet-rich plasma and washed platelets with IC50 values of 31 and 21 nM, respectively.1 13,14-dh PGE1 is a slightly more potent inhibitor of ADP-induced human platelet aggregation than PGE1 which has an IC50 of 40 nM.2 Also, 13,14-dh PGE1 activates adenylate cyclase in NCB-20 hybrid cells with a Kact of 668 nM.3WARNING This product is not for human or veterinary use.
References
[1] G. KOBZAR. Comparison of the inhibitory effect of E-prostaglandins in human and rabbit platelet-rich plasma and washed platelets[J]. Comparative Biochemistry and Physiology Part C: Pharmacology, Toxicology and Endocrinology, 1993, 106 2: Pages 489-494. DOI:
10.1016/0742-8413(93)90168-k[2] I. JÄRVING. ANTIAGGREGATING POTENCY OF E-TYPE PROSTAGLANDINS IN HUMAN AND RABBIT PLATELETS[J]. Proceedings of the Estonian Academy of Sciences. Chemistry, 1991, 32 1. DOI:
10.3176/chem.1991.3.09[3] I.A. BLAIR J. M C N HENSBY. PROSTACYCLIN-DEPENDENT ACTIVATION OF ADENYLATE CYCLASE IN A NEURONAL SOMATIC CELL HYBRID: PROSTANOID STRUCTURE-ACTIVITY RELATIONSHIPS[J]. British Journal of Pharmacology, 1980, 69 3: 519-525. DOI:
10.1111/j.1476-5381.1980.tb07043.x
